Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed that all agenda items presented at its 14th Annual General Meeting (AGM) of Shareholders—including approval of financial statements, amendments to the articles of incorporation, appointments of directors and audit committee members, and approval of director remuneration limits—were approved as originally proposed.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Results of Annual General Meeting of Shareholders
- AGM Date: March 14, 2025
- Approval of FY2024 Financial Statements (Unit: KRW million, Audit Opinion: Unqualified):
- Consolidated: Total Assets 17,336,296 / Total Liabilities 6,431,620 / Total Equity 10,904,676 / Revenue 4,547,322 / Operating Profit 1,320,052 / Net Profit 1,083,316 (EPS KRW 15,221)
- Separate: Total Assets 13,317,211 / Total Liabilities 4,036,318 / Total Equity 9,280,893 / Revenue 3,497,146 / Operating Profit 1,321,426 / Net Profit 1,050,967 (EPS KRW 14,766)
- Dividend Details: Not stated (-)
- Voting Results on Major Agenda Items:
- Item 1: Approval of FY2024 Financial Statements ➔ Approved as proposed
- Item 2: Amendments to the Articles of Incorporation ➔ Approved as proposed
- Item 3: Appointment of Directors
- Item 3-1: Appointment of Executive Director Seung-ho Yoo (New, 3-year term) ➔ Approved as proposed
- Item 3-2: Appointment of Independent Director Ho-seung Lee (New, 3-year term) ➔ Approved as proposed
- Item 4: Appointment of Independent Director Chang-woo Lee as Audit Committee Member (Re-appointment, 3-year term) ➔ Approved as proposed
- Item 5: Appointment of Ho-seung Lee as Audit Committee Member (New, 3-year term) ➔ Approved as proposed
- Item 6: Approval of Director Remuneration Limit ➔ Approved as proposed
- Post-AGM Board Composition:
- Total Directors: 7 (4 Independent Directors, representing 57.14%)
- Audit Committee Members: 3 (All Independent Directors)
- Related Disclosures:
- February 12, 2025: Decision to Convene Annual General Meeting of Shareholders
- February 27, 2025: Convocation Notice and Reference Materials for AGM
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Approval of AGM Resolutions and New Board Structure
This disclosure provides notice that all proposed agenda items at Samsung Biologics’ 14th AGM have been approved as presented.
Checking the newly finalized Board composition—including the appointments of Executive Director Seung-ho Yoo and Independent Director Ho-seung Lee, along with the re-appointment of Independent Director Chang-woo Lee—and tracking upcoming annual report filings is essential.
Relevant details can be verified in subsequent periodic filings (Annual Report) and official disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
